Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia

BACKGROUND: Resistance developed by leukemic cells, unsatisfactory efficacy on patients with chronic myeloid leukemia (CML) at accelerated and blastic phases, and potential cardiotoxity, have been limitations for imatinib mesylate (IM) in treating CML. Whether low dose IM in combination with agents...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hu, Zheng, Pan, Xiao-Fen, Wu, Fu-Qun, Ma, Li-Yuan, Liu, Da-Peng, Liu, Ying, Feng, Ting-Ting, Meng, Fan-Yi, Liu, Xiao-Li, Jiang, Qian-Li, Chen, Xiao-Qin, Liu, Jing-Lei, Liu, Ping, Chen, Zhu, Chen, Sai-Juan, Zhou, Guang-Biao
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2009
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2705802/
https://ncbi.nlm.nih.gov/pubmed/19606213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0006257
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares